Chief Financial Officer · Summit Therapeutics Inc. (SMMT)

Michael Donaldson

FY2020 is the first fiscal year CompBrief holds for Michael Donaldson as a named executive officer of Summit Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$961,418

Salary $206,731Stock awards $0Bonus $79,859

1st of 5 named executive officers at Summit Therapeutics by FY2020 total.

6 named officers on file for Summit Therapeutics, FY2020

Michael Donaldson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Summit Therapeutics’s whole pay program stands against its peers

  • Summit Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SMMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2021 (DEF 14A).

Free

Get Michael Donaldson’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Donaldson compensation by year

Summit Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Summit Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$206,731
Bonus$79,859
Stock awards$0
Option awards$665,220
Non-equity incentive$0
Pension and deferred compensation$0
All other$9,608
Total$961,418

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Summit Therapeutics Inc. DEF 14A filed April 29, 2021, accession 0000921895-21-001172, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Summit Therapeutics Inc. filed document, accession 0000921895-21-001172. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option257,761—$3.52
Option300,000—$3.52

Per the Outstanding Equity Awards at Fiscal Year-End table in Summit Therapeutics Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Summit Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Michael Donaldson · this pageChief Financial Officer$961,418
Ventzislav StefanovFormer Executive Vice President, President of Discuva and Director (4)$674,823
Glyn EdwardsFormer Chief Executive Officer and Director (4)$621,822
Mahkam ZanganehDirector and Chief Operating Officer (3)$527,312
David PowellFormer Chief Scientific Officer$401,124
Robert DugganChief Executive Officer and Executive Chairman (2)—

The full Summit Therapeutics compensation record

free company brief

This page is one person within Summit Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Summit Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Donaldson's compensation dossier · One-time report. No refunds.